マサチューセッツ州における子宮内膜がんの臨床試験
マサチューセッツ州内の拠点で、子宮内膜がんに関する53件の研究が参加者を募集しています。
マサチューセッツ州内の都市
公式研究テキスト（英語）
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- 他1件
被験者募集中第2相
全年齢 · 全性別 · 2026/10/02更新 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 全性別 · 2026/10/02更新 · NCT07059884Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- Dana-Farber Cancer Institute, Boston
被験者募集中第3相
18歳以上 · 女性 · 2026/10/02更新 · NCT07198074A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Dana-Farber Cancer Institute - Oncology Department, Boston
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
19歳以上 · 全性別 · 2026/10/01更新 · NCT06586957Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06218914Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/25更新 · NCT03564340A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
被験者募集中第1/2相
18歳以上 · 女性 · 2026/09/24更新 · NCT04590326Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- Massachusetts General Hospital Cancer Center, Boston
- Baystate Medical Center, Springfield
- UMass Memorial Medical Centre, Worcester
被験者募集中第2相
18歳以上 · 女性 · 2026/09/24更新 · NCT05640999Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Tufts Medical Center ( Site 6052), Boston
被験者募集中第3相
18歳以上 · 女性 · 2026/09/17更新 · NCT06952504A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07109726ALPINE: Maintenance Letrozole/Abemaciclib
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06366347A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
- Research Site, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/11更新 · NCT05123482Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- UMass Memorial Medical Ctr, Worcester
被験者募集中第3相
18歳以上 · 女性 · 2026/09/09更新 · NCT07166094Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 女性 · 2026/09/03更新 · NCT07755436A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06515613DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Boston
被験者募集中第3相
18歳以上 · 女性 · 2026/09/03更新 · NCT06989112Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中
18歳以上 · 女性 · 2026/08/31更新 · NCT04839614A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
- Mass General Cancer Center, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/27更新 · NCT07227168A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/26更新 · NCT07383506Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
12 Months – 30 Years · 全性別 · 2026/08/25更新 · NCT04851119A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06774963Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Boston
被験者募集中第1/2相
18歳〜130歳 · 全性別 · 2026/08/21更新 · NCT05797168A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Dana Farber Cancer Institute, Boston
被験者募集中第2相
18歳以上 · 女性 · 2026/08/21更新 · NCT05548296A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Massachusetts General Hospital, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/19更新 · NCT04104776A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/18更新 · NCT07182149FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/17更新 · NCT05919264A Study of PHST001 in Advanced Solid Tumors
- Dana Farber Cancer Institute, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/12更新 · NCT06840886A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/04更新 · NCT05579366First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/07/07更新 · NCT05768139A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/29更新 · NCT07458347Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/29更新 · NCT05377996Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/23更新 · NCT06993844ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。